You are here:
NICE
NICE Guidance
Conditions and diseases
Cancer
Ovarian cancer
Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy
Technology appraisal guidance
Reference number:
TA598
Published:
28 August 2019
This guidance has been updated and replaced by
NICE technology appraisal guidance 962
.